BNP Paribas Financial Markets
CARM

BNP Paribas Financial Markets’s Carisma Therapeutics CARM Stock Holding History

BNP Paribas Financial Markets’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-347
Closed -$95 – 5758
2025
Q3 		$95 Hold
347
– – ﹤0.01% 5439
2025
Q2 		$136 Hold
347
– – ﹤0.01% 5309
2025
Q1 		$108 Sell
347
-120
-26% -$53 ﹤0.01% 5250
2024
Q4 		$196 Buy
+467
New +$385 ﹤0.01% 5231
2023
Q1 		– Sell
-27
Closed -$330 – 3875
2022
Q4 		$330 Sell
27
-52
-66% -$546 ﹤0.01% 3892
2022
Q3 		$667 Sell
79
-1,428
-95% -$19.4K ﹤0.01% 4492
2022
Q2 		$24.4K Sell
1,507
-768
-34% -$8.79K ﹤0.01% 3677
2022
Q1 		$27.4K Sell
2,275
-193
-8% -$2.7K ﹤0.01% 3678
2021
Q4 		$40.2K Buy
2,468
+712
+41% +$14.3K ﹤0.01% 3772
2021
Q3 		$27.9K Buy
1,756
+1,427
+434% +$68.5K ﹤0.01% 3612
2021
Q2 		$30.4K Buy
+329
New +$21K ﹤0.01% 3423
2015
Q2 		– Sell
-6
Closed -$1.03K – 3551
2015
Q1 		$1.03K Buy
+6
New +$1.31K ﹤0.01% 3551
2014
Q4 		– Sell
-23
Closed -$5.21K – 2162
2014
Q3 		$5.21K Buy
23
+18
+360% +$4.28K ﹤0.01% 3806
2014
Q2 		$1.23K Buy
+5
New +$1.24K ﹤0.01% 3359

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

BNP Paribas Financial Markets's CARM Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 347 shares — an estimated $95 sold.

BNP Paribas Financial Markets first reported a position in CARM in Q2 2014 and held it in 14 quarters. The position peaked at $40.2K in Q4 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 347 Carisma Therapeutics shares in Q4 2025, an estimated $95.
  • BNP Paribas Financial Markets first reported a position in Carisma Therapeutics in Q2 2014 and held it in 14 quarters.
  • BNP Paribas Financial Markets's Carisma Therapeutics position peaked at $40.2K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.